Business Context and Reporting Period
The filing is Diffusion Pharmaceuticals Inc.’s unaudited Form 10-Q for the quarter and nine months ended September 30, 2021—not a filing for Cervomed Inc. Diffusion is a clinical-stage biopharmaceutical company developing trans sodium crocetinate (TSC) to improve oxygen delivery to hypoxic tissues. It reported no product revenue.
Financial Performance and Liquidity
| Metric | Q3 2021 | Q3 2020 | Nine months 2021 | Nine months 2020 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| Research and development expense | $2.1 million | $3.1 million | $7.0 million | $6.8 million |
| General and administrative expense | $1.9 million | $2.1 million | $5.5 million | $5.0 million |
| Net loss | $12.2 million | $4.4 million | $20.6 million | $10.1 million |
| Net loss per share, basic and diluted | $0.12 | $0.07 | $0.22 | $0.24 |
| Operating cash used | Not stated for quarter | Not stated for quarter | $11.5 million | $10.2 million |
Q3 operating loss was $12.7 million, including a noncash $8.6 million impairment of the DFN-529 intangible asset. The company reported a $0.4 million income tax benefit in 2021. Profit margins are not meaningful because the company had no revenue.
At September 30, 2021, cash and cash equivalents were $40.3 million, current assets $40.7 million, current liabilities $2.7 million, working capital $38.0 million, total liabilities $2.7 million, and stockholders’ equity $38.1 million. The filing reports no credit facilities or committed capital. Cash increased $21.8 million over the first nine months, principally reflecting $33.3 million of financing proceeds, including the February equity offering and warrant exercises. Shares outstanding at quarter-end were 101.9 million, up from 64.0 million at December 31, 2020.
Changes Versus Prior Comparable Period
- Q3 net loss rose by $7.8 million year over year, largely due to the $8.6 million DFN-529 impairment; excluding this unusual noncash charge, reported operating expenses were lower overall in Q3.
- Nine-month net loss increased by $10.5 million. The impairment was the principal unusual expense; R&D and G&A also increased modestly.
- Nine-month operating cash use increased by $1.3 million. Financing proceeds increased to $33.3 million from $17.9 million.
- The February 2021 public offering raised $31.1 million net and contributed to substantial share-count growth and dilution.
Outlook, Commentary, and Risks
- Management said September 30 cash was expected to fund operating expenses and capital requirements through 2023, while noting additional financing would be needed to complete TSC development. No assurance was given that financing would be available on acceptable terms.
- Management planned to seek FDA feedback on the proposed hypoxic solid tumor development plan in Q1 2022. The first study, expected to be a Phase 2 trial, depended on FDA feedback and clinical drug supply.
- The TCOM trial showed a reported positive dose-response trend in peripheral oxygenation. The Altitude and ILD-DLCO trials were planned, with topline results anticipated in the first half of 2022; these were expectations, not reported outcomes.
- TSC manufacturing faced delays and interruptions because the primary contract manufacturer’s facility was producing COVID-19 vaccines. Supply availability, manufacturing changes, costs, and trial timing remained risks.
- DFN-529 development was abandoned and its asset fully impaired. The filing also describes a former executive’s lawsuit returned to state court; the company disputed the claims but could not estimate a possible loss.
- Nasdaq granted an extension through May 2, 2022 to regain the $1.00 minimum bid-price requirement. A reverse stock split was among the alternatives under consideration; continued listing was not assured.
- After quarter-end, the company agreed to terminate its office lease early for a one-time payment of about $14,000 and moved to short-term coworking arrangements.
- The company expected continued substantial losses and higher development spending. It cited potential dilution from future equity financing and possible disruption or delay of development if funding could not be obtained.
Key Facts for Investors to Verify
- Confirm the registrant identity: the supplied filing names Diffusion Pharmaceuticals Inc., although the request metadata names Cervomed Inc.
- Track cash burn, financing needs, and whether the stated runway through 2023 remains achievable.
- Verify progress, results, and timing for the Altitude, ILD-DLCO, and planned hypoxic solid tumor studies, including FDA feedback and clinical drug supply.
- Monitor TSC manufacturing resilience and the impact of supply constraints on trial timing and costs.
- Assess the Nasdaq bid-price compliance deadline and any reverse split decision, alongside continuing dilution and the unresolved litigation.